Ultragenyx Pharmaceutical (RARE) Gross Profit: 2016-2025
Historic Gross Profit for Ultragenyx Pharmaceutical (RARE) over the last 8 years, with Sep 2025 value amounting to $131.9 million.
- Ultragenyx Pharmaceutical's Gross Profit rose 11.37% to $131.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $534.0 million, marking a year-over-year increase of 18.45%. This contributed to the annual value of $483.5 million for FY2024, which is 24.28% up from last year.
- Ultragenyx Pharmaceutical's Gross Profit amounted to $131.9 million in Q3 2025, which was down 8.05% from $143.5 million recorded in Q2 2025.
- Ultragenyx Pharmaceutical's 5-year Gross Profit high stood at $148.0 million for Q4 2024, and its period low was $73.8 million during Q1 2022.
- In the last 3 years, Ultragenyx Pharmaceutical's Gross Profit had a median value of $115.3 million in 2023 and averaged $114.4 million.
- Its Gross Profit has fluctuated over the past 5 years, first skyrocketed by 187.16% in 2021, then declined by 21.62% in 2022.
- Ultragenyx Pharmaceutical's Gross Profit (Quarterly) stood at $79.9 million in 2021, then grew by 22.72% to $98.0 million in 2022, then grew by 17.66% to $115.3 million in 2023, then increased by 28.30% to $148.0 million in 2024, then grew by 11.37% to $131.9 million in 2025.
- Its Gross Profit stands at $131.9 million for Q3 2025, versus $143.5 million for Q2 2025 and $110.6 million for Q1 2025.